Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

NCT03366688 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: IBI306
DRUG: placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.